ReviewFrontiers in medicine2026
Overview of clear cell renal cell carcinoma: from mechanisms to clinical.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell renal cell carcinoma is the most common histological subtype of kidney cancer, and its development is often related to mutations in the VHL gene. Inactivation of the VHL gene leads to accumulation of HIF-2α. The accumulation of HIF-2α activates multiple signaling pathways, promoting tumor growth and proliferation. The treatment strategies for clear cell renal cell carcinoma mainly include surgical resection, targeted drugs, and immune checkpoint inhibitors. Previous targeted treatments have mostly been tyrosine kinase inhibitors. In recent years, the HIF-2α inhibitor Belzutifan has been approved by the FDA for the treatment of clear cell renal cell carcinoma due to its specificity in blocking the HIF-2α signaling pathway and its ability to inhibit tumor growth. This article, based on HIF-2α, provides an overview of the pathogenesis, diagnosis, and treatment of clear cell renal cell carcinoma, with a focus on the clinical trial results of Belzutifan, offering direction and information for the clinical treatment of clear cell renal cell carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.